MGT Comments on American Cancer Society's Decision to Endorse CT Co...( NEW YORK Mar. 7 /- MGT Capital In...),Health

NEW YORK, Mar. 7 /PRNewswire-FirstCall/ -- MGT Capital Investments, Inc. (Amex: MGT), a holding company focused on the Healthcare Information Technology ("HCIT") sector, today commented on the American Cancer Society's (ACS) decision to add Computerized Tomography Colonography ("CTC") to its colon cancer screening guidelines. MGT Capital Investment's Medicsight PLC subsidiary, traded in London on the AIM exchange under "MDST," is an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software that assists in the early detection and diagnosis of disease.

The ACS said, "Provided that advanced, proven techniques are employed in the clinical setting, CTC is included in the guidelines as an option for colorectal cancer screening and prevention in average-risk adults aged 50 years and older."

The guidelines reflect the growing endorsement for CTC screening, also known as virtual colonoscopy ("VC"), by the ACS and the ACR, and by the three major gastrointestinal societies: the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (AGSE), and the American College of Gastroenterology (ACG).

David Sumner, Chief Executive of Medicsight, said, "We are delighted that the ACS has decided to include CTC in the panel of tests that physicians have at their disposal when screening for colorectal cancer. The ACS endorsement is expected to lead to routine reimbursement for CTC and thereby to a material increase in the use of CTC for screening those populations who are most at risk of developing this devastating condition. Medicsight's ColonCAD(TM) software for CT imaging equipment helps radiologists to interpret CT scans and to identify early-stage lesions.
'/>"/>